Tagrisso Shows Proven Progression-Free Survival Benefit in EGFR Mutant Lung Cancer Treatment

The post Tagrisso Shows Proven Progression-Free Survival Benefit in EGFR Mutant Lung Cancer Treatment appeared first on News Directory 3.
Proven progression-free survival benefit … the possibility of first-line targeted treatment [의약뉴스] AstraZeneca’s Tagrisso (ingredient name: osimertinib) was found to have excellent efficacy in treating stage 3 EGFR (epidermal growth factor receptor) mutant lung cancer in a phase 3 clinical trial. In the phase 3 LAURA clinical trial, AstraZeneca found that Tagrisso improved progression-free survival […]